Advertisement
Advertisement
TOPIC

Made in China 2025

Made in China 2025
Launched by Premier Li Keqiang in 2015, the “Made in China 2025" strategy aims to guide the country’s industrial modernisation, including the substitution of foreign technology with innovation developed on the mainland.
The US$60 billion deal value represents a 73 per cent jump from the same period a year earlier. Photo: Shutterstock
Biomedicine: Companies

China biotech deals hit record as innovative drugs draw global interest

Deals reach US$60 billion in first quarter after analysts say Chinese biotech firms have shown substantial technological advancements.

Biomedicine: Companies

Global drug giants double down on China amid push for self-reliant supply chains

Biomedicine: Companies

China biotech outlicensing tops US$52 billion in first 2 months

China technology

Xiaomi tests humanoid robots as firm plans to deploy ‘large number’ in 5 years

Xiaomi robots operated autonomously for three continuous hours, successfully completing assembly tasks without human intervention.

Xiaomi’s CEO and chairman, Lei Jun, said a trial in the firm’s car production facility saw robots operating autonomously for three continuous hours, successfully completing assembly tasks without human intervention. Photo: Xiaomi
Biomedicine: Companies

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

China economy

Opinion | How ‘little giants’ help China defend its manufacturing dominance

Support for ‘little giants’ and other specialised SMEs remains a vital part of the long-term strategy to bolster China’s global manufacturing.

videocam
Advertisement
Advertisement
Advertisement
Biomedicine: Industry Trends

After boost from viral dance challenge, Chinese medicine firm’s shares languish

Slumping profits at Shandong Xinhua Pharmaceutical have dragged the shares to about HK$7 in December 2025 from HK$15.62 in December 2022.

The combined daily production capacity of ibuprofen and paracetamol in China surged fourfold to 202 million tablets by late December 2022. Photo: Shutterstock
China economy

Opinion | How the next China shock is shaping hearts and minds

No longer confined to trade and technology, competition between China and the West is now playing out in the realm of cultural imagination.

videocam
Biomedicine: Industry Trends

Capital injection: China backs AI drug makers in self-reliance drive

A wave of government-linked investment is boosting Chinese AI drug makers, underscoring Beijing’s drive to build its own biotech ecosystem.

Biomedicine: Companies

Chinese healthcare firms expand overseas to support growing expat community

Privately owned Distinct Healthcare plans to open a clinic in Dubai, while TCM group Gushengtang eyes 50 centres in Southeast Asia.

Distinct Healthcare raised HK$284.53 million from its initial public offering in Hong Kong last week. Photo: Handout
Biomedicine: Industry Trends

Fosun Pharma unit licenses lung cancer drug to Eisai in US$1.55 billion deal

The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners.

A view of the Shanghai facility of Fosun Pharma’s biopharma unit Henlius. Photo: Handout
IPO

Morgan Stanley sees another record year for Hong Kong IPOs as pipeline hits 450

Mainland China’s issuers will still dominate city’s IPO market, executive says, but US and Southeast Asian companies are also joining in.

Biomedicine: Geopolitics

Exclusive | China challenges US in AI drug race, but rivals still reliant on each other

While US biotech firms increase use of Chinese clinical data, Chinese firms need US counterparts for monetisation, investor and scientist says.

Biomedicine: Industry Trends

Novartis, SciNeuro deal offers hope for 55 million suffering from Alzheimer’s

SciNeuro’s anti-amyloid programme is one of the firm’s key strategic research and development priorities to target the brain disease.

videocam
Swiss drugmaker Novartis has gained global rights over SciNeuro’s novel amyloid beta targeted antibody programme. Photo: Reuters
Biomedicine: Industry Trends

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.

There were more than 400 million overweight or obese adults in China in 2021, according to a study. Photo: Getty Images
Biomedicine: Companies

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Biomedicine: Industry Trends

Meow or never: China’s pudgy pets spark race for weight-loss drugs

Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.

Advertisement
Advertisement
Advertisement
China manufacturing

China’s next decade to cement status as hi-tech manufacturing power: reports

The coming 10 years will see significant advances in cutting-edge sectors, reinforcing industrial dominance, according to new reports.

videocam
7
Robots carry out welding operations at the FAW-Volkswagen production based in Jimo district, Qingdao, eastern China’s Shandong province, on February 19. Photo: AFP
Mainland China

Chinese firms flock to Dubai free zones to navigate trade barriers, expand reach

JD.com, CNBM, carmakers and hundreds of other Chinese companies use the hub to reach consumers across Asia, Africa and Europe.

Biomedicine: Industry Trends

China’s rising biotech clout on show in flurry of billion-dollar licensing deals

A burst of overseas licensing pacts is spotlighting China’s biotech sector, as Jacobio, Coherent Biopharma and Harbour BioMed land deals.

China economy

Opinion | Arguing about China’s overcapacity overlooks its drive for clean energy

What is often described as overcapacity is the outcome of a development strategy that treats energy as the foundation of economic capability.

videocam
Fields of solar panels at a power station in Weining, Guizhou province, in China on July 3. Photo: Xinhua
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

US drugmakers are increasingly looking to Chinese biotechs as an answer to the revenue gaps left by the looming ‘patent cliff’. Illustration by Henry Wong
Biomedicine: Industry Trends

China’s pharmaceutical industry transforms into a global innovation powerhouse

The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.

Mainland China

Can rising lithium costs save China’s energy storage firms from a price war?

China’s battery makers raise prices amid lithium rebound and global AI energy demand.

Biomedicine: Policy

China’s new drug insurance: lifeline for patients or squeeze on big firms?

New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.

The commercial insurance formulary covers some medicines that are not yet eligible for reimbursement under the country’s National Reimbursement Drug List. Photo: Shutterstock
Biomedicine: Companies

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.

A number of Chinese biotech firms have clinched licensing deals with multinational companies this year. Photo: Shutterstock
Robotics

China’s Unitree teases platform allowing users to control robots via smartphones

Hangzhou robotics unicorn’s platform is designed to bring embodied intelligence into everyday life.

Biomedicine: Companies

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

Yao Pharma’s deal with the US pharmaceutical giant underscores China’s growing role in global biotech licensing.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement